DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

1662 Jayasekara D, Aweeka FT, Rodriguez R, et al. Antiviral therapy
for HIV patients with renal insufficiency. J Acquir Immune
Defic Syndr, 1999, 21:384–395.
Jiang S, Lin K, Strick N, Neurath AR. HIV-1 inhibition by a peptide.
Nature, 1993, 365:113.
Khoo SH, Back DJ, Merry C. Pharmacology. In: Practical
Guidelines in Antiviral Therapy (Boucher CAB, Galasso GAJ,
eds.), Elsevier, Amsterdam, 2002, pp. 13–35.
Kieffer TL, Finucane MM, Nettles RE, et al. Genotypic analysis
of HIV-1 drug resistance at the limit of detection: Virus production
without evolution in treated adults with undetectable
HIV loads. J Infect Dis, 2004, 189:1452–1465.
Kim RB, Fromm MF, Wandel C, et al. The drug transporter P-
glycoprotein limits oral absorption and brain entry of HIV-1
protease inhibitors. J Clin Invest, 1998, 101:289–294.
Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus
deferred antiretroviral therapy for HIV on survival. N Engl
J Med, 2009, 360:1815–1826.
Kuritzkes DR. Preventing and managing antiretroviral drug
resistance. AIDS Patient Care STDs, 2004, 18:259–273.
Kuritzkes DR, Marschner I, Johnson VA, et al. Lamivudine in
combination with zidovudine, stavudine, or didanosine in
patients with HIV-1 infection: A randomized, double-blind,
placebo-controlled trial. National Institute of Allergy and
Infectious Disease AIDS Clinical Trials Group Protocol 306
Investigators. AIDS, 1999, 13:685–694.
Larder BA, Kemp SD, Harrigan PR. Potential mechanism for
sustained antiretroviral efficacy of AZT-3TC combination therapy.
Science, 1995, 269:696–699.
Lawrence J, Mayers DL, Hullsiek KH, et al., for the 064 Study
Team of the Terry Beirn Community Programs for Clinical
Research on AIDS. Structured treatment interruption in
patients with multi-drug-resistant human immunodeficiency
virus. N Engl J Med, 2003, 349:837–846.
Lee H, Hanes J, Johnson KA. Toxicity of nucleoside analogues
used to treat AIDS and the selectivity of the mitochondrial
DNA polymerase. Biochemistry, 2003, 42:14711–14719.
Lee LM, Karon JM, Selik R, et al. Survival after AIDS diagnosis
in adolescents and adults during the treatment era, United
States, 1984–1997. JAMA, 2001, 285:1308–1315.
Leung NW, Lai CL, Chang TT, et al., on behalf of the Asia
Hepatitis Lamivudine Study Group. Extended lamivudine
treatment in patients with chronic hepatitis B enhances hepatitis
B e antigen sero-conversion rates: Results after 3 years of
therapy. Hepatology, 2001, 33:1527–1532.
Lockman S, Shapiro RL, Smeaton LM, et al. Response to antiretroviral
therapy after a single, peripartum dose of nevirapine.
N Engl J Med, 2007, 356:135–147.
MacArthur RD, Novak RM. Maraviroc: The first of a new class
of antiretroviral agents. Clin Infect Dis, 2008, 47:236–241.
Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for
hypersensitivity to abacavir. N Engl J Med, 2008, 358:568–579.
Manabe YC, Campbell JD, Sydnor E, Moore RD. Immune
reconstitution inflammatory syndrome: Risk factors and treatment
implications. J Acquir Immune Defic Syndr, 2007,
46:456–462.
McDowell JA, Chittick GE, Stevens CP, et al. Pharmacokinetic
interaction of abacavir (1592U89) and ethanol in human
immunodeficiency virus–infected adults. Antimicrob Agents
Chemother, 2000, 44:1686–1690.
SECTION VII
CHEMOTHERAPY OF MICROBIAL DISEASES
McKeage K, Perry CM, Keam SJ. Darunavir: A review of its use
in the management of HIV infection in adults. Drugs, 2009,
69:477–503.
McLeod GX, Hammer SM. Zidovudine: Five years later. Ann
Intern Med, 1992, 117:487–501.
Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and
CD4+ lymphocytes as prognostic markers of HIV-1 infection.
Ann Intern Med, 1997, 126:946–954.
Mellors JW, Rinaldo CR Jr, Gupta P, et al. Prognosis in HIV-1
infection predicted by the quantity of virus in plasma. Science,
1996, 272:1167–1170.
Miller MD, Anton KE, Mulato AS, et al. Human immunodeficiency
virus type 1 expressing the lamivudine-associated
M184V mutation in reverse transcriptase shows increased susceptibility
to adefovir and decreased replication capability in
vitro. J Infect Dis, 1999, 179:92–100.
Mirochnick M, Fenton T, Gagnier P, et al. Pharmacokinetics of nevirapine
in human immunodeficiency virus type 1–infected pregnant
women and their neonates. Pediatric AIDS Clinical Trials
Group Protocol 250 Team. J Infect Dis, 1998, 178: 368–374.
Mitsuya H, Weinhold KJ, Furman PA, et al. 3′-Azido-3′-
deoxythymidine (BW A509U): An antiviral agent that inhibits
the infectivity and cytopathic effect of human T-lymphotropic
virus type III/lymphadenopathy-associated virus in vitro. Proc
Natl Acad Sci USA, 1985, 82:7096–7100.
Molla A, Vasavanonda S, Kumar G, et al. Human serum attenuates
the activity of protease inhibitors toward wild-type and
mutant human immunodeficiency virus. Virology, 1998,
250:255–262.
Moore KH, Barrett JE, Shaw S, et al. The pharmacokinetics of
lamivudine phosphorylation in peripheral blood mononuclear
cells from patients infected with HIV-1. AIDS, 1999,
13:2239–2250.
Moreno S, Hernández B, Dronda F. Didanosine enteric-coated
capsule: Current role in patients with HIV-1 infection. Drugs,
2007, 67:1441–1462.
Muller V, Bonhoeffer S. Mathematical approaches in the study of
viral kinetics and drug resistance in HIV-1 infection. Curr
Drug Targets Infect Disord, 2003, 3:329–344.
Naeger LK, Margot NA, Miller MD. ATP-dependent removal of
nucleoside reverse transcriptase inhibitors by human immunodeficiency
virus type 1 reverse transcriptase. Antimicrob
Agents Chemother, 2002, 46:2179–2184.
Nettles RE, Kieffer TL, Kwon P, et al. Intermittent HIV-1
viremia (blips) and drug resistance in patients receiving
HAART. JAMA, 2005, 293:817–829.
Noble S, Faulds D. Saquinavir: A review of its pharmacology
and clinical potential in the management of HIV infection.
Drugs, 1996, 52:93–112.
Noor MA, Seneviratne T, Aweeka FT, et al. Indinavir acutely
inhibits insulin-stimulated glucose disposal in humans: A randomized,
placebo-controlled study. AIDS, 2002, 16:F1–F8.
Oldfield V, Plosker GL. Lopinavir/ritonavir: A review of its use
in the management of HIV infection. Drugs, 2006, 66:
1275–1299.
Orman JS, Perry CM. Tipranavir: A review of its use in the management
of HIV infection. Drugs, 2008, 68:1435–1463.
Pauwels R, Andries K, Desmyter J, et al. Potent and selective
inhibition of HIV-1 replication in vitro by a novel series of
TIBO derivatives. Nature, 1990, 343:470–474.